Keylika
About Keylika
Keylika has developed a proprietary transdermal iron patch that utilizes advanced nanotechnology for direct absorption of iron into the bloodstream, bypassing gastrointestinal side effects associated with traditional oral supplements. This solution addresses the widespread issue of iron deficiency anemia by providing a self-administered, highly bioavailable alternative that combines the efficacy of intravenous iron with the convenience of oral delivery.
<problem> Iron deficiency anemia (IDA) affects millions globally, leading to fatigue, shortness of breath, and impaired daily functioning. Current treatments, such as oral iron supplements, often have poor absorption and cause gastrointestinal side effects, leading to patient non-compliance. Intravenous (IV) iron infusions offer better bioavailability but are invasive, costly, and carry a risk of hypersensitivity reactions. </problem> <solution> Keylika is developing a novel transdermal iron patch (NistuFe) that delivers a proprietary iron form directly into the bloodstream, bypassing the gastrointestinal tract and associated side effects. The patch combines the efficacy of IV iron with the convenience of oral supplements, offering a patient-friendly alternative for managing IDA. Keylika's approach utilizes a new molecular entity (KYLK01), a small molecule (<500 Da) mixed ligand iron complex, designed for enhanced absorption and bioavailability through the skin. Pre-clinical studies have demonstrated excellent iron uptake and improved hematological parameters without systemic toxicity. The resorbable buccal patch adheres to the inner cheek and dissolves in under an hour, releasing the iron drug for transmucosal absorption. </solution> <features> - Transdermal patch for direct absorption of iron into the bloodstream - New molecular entity (NME) - KYLK01, a small molecule (<500 Da) mixed ligand iron complex - Designed to bypass the gastrointestinal tract, eliminating GI side effects - Higher bioavailability compared to oral iron supplements - Self-administrable and non-invasive - Resorbable buccal patch that dissolves in under an hour - Demonstrated excellent iron uptake and improved hematological parameters in pre-clinical studies - Ligands selected to enhance iron absorption and serve as an antioxidant - Ferric ion (Fe3+) form of iron aids in seamless uptake by the iron protein transporter (transferrin) in blood plasma </features> <target_audience> The primary target audience includes individuals with iron deficiency anemia, particularly women of childbearing age and those who experience adverse effects from oral iron supplements or prefer a non-invasive treatment option. </target_audience>
What does Keylika do?
Keylika has developed a proprietary transdermal iron patch that utilizes advanced nanotechnology for direct absorption of iron into the bloodstream, bypassing gastrointestinal side effects associated with traditional oral supplements. This solution addresses the widespread issue of iron deficiency anemia by providing a self-administered, highly bioavailable alternative that combines the efficacy of intravenous iron with the convenience of oral delivery.
Where is Keylika located?
Keylika is based in Walnut Creek, United States.
When was Keylika founded?
Keylika was founded in 2022.
How much funding has Keylika raised?
Keylika has raised 740000.
Who founded Keylika?
Keylika was founded by Buddhadev Chaudhuri and Frederik Ceyssens.
- Buddhadev Chaudhuri - CEO/Co-Founder
- Frederik Ceyssens - Founder
- Location
- Walnut Creek, United States
- Founded
- 2022
- Funding
- 740000
- Employees
- 2 employees